Herpes zoster (HZ; shingles)--a reactivation of the latent varicella zoster virus (VZV)--can cause significant morbidity. Its major complication is pain, particularly post-herpetic neuralgia (PHN). We will review the current management strategies available for the treatment of both acute HZ and PHN, including antiviral drugs, analgesic agents, anticonvulsants, tricyclic antidepressants and topical therapies. New molecules in development that show improved activity against VZV are also covered, and new drug targets are outlined. The role of translational neuroscience in moving towards a goal of finding disease-modifying treatments will be examined.
Whitley, R., Volpi, A., Mckendrick, M., Wijck, A., Oaklander, A. (2010). Management of herpes zoster and post-herpetic neuralgia now and in the future. JOURNAL OF CLINICAL VIROLOGY, 48(suppl. 1), 20-28 [10.1016/S1386-6532(10)70005-6].
Management of herpes zoster and post-herpetic neuralgia now and in the future
VOLPI, ANTONIO;
2010-05-01
Abstract
Herpes zoster (HZ; shingles)--a reactivation of the latent varicella zoster virus (VZV)--can cause significant morbidity. Its major complication is pain, particularly post-herpetic neuralgia (PHN). We will review the current management strategies available for the treatment of both acute HZ and PHN, including antiviral drugs, analgesic agents, anticonvulsants, tricyclic antidepressants and topical therapies. New molecules in development that show improved activity against VZV are also covered, and new drug targets are outlined. The role of translational neuroscience in moving towards a goal of finding disease-modifying treatments will be examined.| File | Dimensione | Formato | |
|---|---|---|---|
|
future.pdf
solo utenti autorizzati
Dimensione
290.7 kB
Formato
Adobe PDF
|
290.7 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
